Results 111 to 120 of about 1,466,333 (379)

Producing and prospects for the use of bispecific antibodies for the treatment of cancer

Успехи молекулярной онкологии, 2019
Bispecific antibody molecules contain two different antigen-binding centers. Particular interest in bispecific antibodies is due to their therapeutic application.
S. E. Sedykh, G. A. Nevinsky
doaj   +1 more source

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]

, 2016
Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa, Curiel, David T, Mathis, J. Michael, O\u27Bryan, Samia M, Rivera, Angel A   +4 more
core   +3 more sources

Development of a DNA Aptamer‐Based Approach to Noninvasively Image CAR‐T Cells In Vivo and Traceless Enrichment In Vitro

Advanced Science, EarlyView.
A DNA aptamer (A3) with nanomolar affinity for CAR‐T cells is developed via Cell‐SELEX. In Nalm6 tumor‐bearing mice, Cy5‐labeled A3 enables long‐term fluorescence imaging and tracks the biodistribution of CAR‐T cells, with tumor signal peaking on day 14 after CAR‐T cell administration.
Minghui Chen, Pengzhao Chang, Zhen Zhang, Dan Liu, Rui Hou, Ming Shi, Jingjing Li, Kai Xu, Junnian Zheng   +8 more
wiley   +1 more source

Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies

OncoTargets and Therapy
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described.
Wen, Xiaoli, Xu, Gaosi
openaire   +2 more sources

Harnessing MerTK agonism for targeted therapeutics

mAbs, 2020
Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies.
Vivekananda Kedage, Diego Ellerman, Yongmei Chen, Wei-Ching Liang, Joven Borneo, Yan Wu, Minhong Yan   +6 more
doaj   +1 more source

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]

, 2013
Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini, A Pfosser, A Thakur, A Thakur, A Thakur, A Yamauchi, AB Heimberger, Archana Thakur, AT Ogden, BF Skinnider, G Jung, GA Niehans, Geoffrey R Barger, HE Lum, Ian M Zitron, J O’Connell, JF Mineo, JK Chan, JM Gall, K Ohshima, K Shiraki, KO Nam, L Davico Bonino, L Ren-Heidenreich, Lawrence G Lum, LG Lum, LM Weiner, M Al-Hajj, M Hahne, M Hishii, M Kawakami, M Sen, M Yankelevich, N Husain, Oxana Norkina, P Saas, PA Davol, RC Grabert, RO Dillman, Sandeep Mittal, SK Jacobs, SK Singh, T Hida, T Nishimura, T Nishimura, T Nitta, TA Dolecek, U Kapp, U Reusch, V Kolenko, X Yuan, Y Oshima   +51 more
core   +2 more sources

Bioinspired Prolactin Pulse Release from Responsive Microneedles for Inhibiting Fatty Liver Formation

Advanced Science, EarlyView.
Inspired by the prolactin secretion profile under normal physiological conditions, biomimetic prolactin‐releasing microneedles are designed. Under the control of near infrared (NIR), these responsive microneedles facilitate pulsed release of prolactin to inhibit fatty liver formation.
Hongli Yin, Wenjuan Tang, Danqing Huang, JingJing Gan, Pengzi Zhang, Yuanjin Zhao, Yan Bi   +6 more
wiley   +1 more source

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Clinical Cancer Research, 2020
Purpose: With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer.
M. Lakins, A. Koers, R. Giambalvo, J. Munoz-Olaya, R. Hughes, E. Goodman, S. Marshall, F. Wollerton, Sarah Batey, D. Gliddon, M. Tuna, N. Brewis   +11 more
semanticscholar   +1 more source

EXTH-08. REPLACEMENT OF MICROGLIA BY BRAIN-ENGRAFTED MACROPHAGES PREVENTS MEMORY DEFICITS AFTER THERAPEUTIC WHOLE-BRAIN IRRADIATION [PDF]

, 2019
Microglia have a distinct origin compared to blood circulating myeloid cells. Under normal physiological conditions, microglia are maintained by self-renewal, independent of hematopoietic progenitors. Following genetic or pharmacologic depletion, newborn
Boosalis, Zoe, Chen, David, Feng, Xi, Gupta, Nalin, Gupta, Sonali, Liu, Sharon, Rosi, Susanna   +6 more
core   +1 more source

Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy [PDF]

, 2015
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
Achilefu, Samuel, Ai, Guanhua, Ding, Li, Feng, Song, Fida, Guissi, Gu, Yueqing, Ma, Yuxiang, Tian, Caiping, Zhang, Congying   +8 more
core   +2 more sources